Plasma Fractionation Market by Product, Application & by End-user - Global Forecast to 2019

Over the last five years, the plasma fractionation market witnessed tremendous growth, primarily due to the growth in aging population, increasing number of hemophilic patients, rising use of IVIg, and high prevalence of chronic disorders across the globe.

In this report, the global plasma fractionation market is divided on the basis of product, application, and end user. Based on type of products, the plasma fractionation market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. Coagulation factor concentrates are subsegmented into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates. The plasma fractionation application market is divided into neurology; hematology; immunology; critical care; and others. Likewise, the major end users analyzed in the plasma fractionation market are hospitals and clinics, clinical research laboratories, and academic institutes.

The global plasma market is expected to grow at a CAGR of 8.9% during the forecast period of 2014–2019. The market is mainly driven by the growth in aging population, increasing use of IVIg, growing number of hemophilic patients, and increasing diagnosis rate globally. However, the high cost of immunoglobulins and hemophilic drugs, stringent government regulations, and rapid increase in the use of recombinant products as an alternative to plasma-derived coagulation factor concentrates are hampering the growth of this market to a certain extent.

IVIg accounts for the major share of the plasma fractionation market. The increasing use of IVIg in clinical areas such as neurology, hematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg is being evaluated for a wide range of conditions such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer’s disease. Positive results in such conditions would increase the demand for IVIg globally in the near future.

In 2013,, North America contribute the largest share to the global plasma fractionation market, followed by Europe, Asia-Pacific, and RoW. Developed geographies like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market, which is expected to witness the fastest growth during the forecast period, largely driven by the increasing aging population, increasing use of immunoglobulins, improved economy, rising number of hemophilic patients, growing use of albumin in China, increased accessibility to healthcare facilities, growth in the overall healthcare industry, and growing awareness of technologically advanced products in these regions.

The global plasma fractionation market is mainly dominated by six players that accounted for around 70% of the global plasma fractionation market in 2013. The major players in the global plasma fractionation market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland), Laboratoire Francais du Fractionnement et des Biotechnologies (France), and Biotest (Germany).

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies (Market Penetration, Product Development/Innovation, Market Development, Market Diversification, and Competitive Assessment) for reaping greater market share.

This report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on product portfolios offered by top players in the plasma fractionation market. The report analyzes the plasma products by products, applications, and end users across all regions.
‧ Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the plasma fractionation market.
‧ Market Development: Comprehensive information on the lucrative emerging markets by products, application, end users, and region.
‧ Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the plasma fractionation market.
‧ Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and SWOT analysis of leading players in the plasma fractionation market.

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED IN THE STUDY 18
1.4 CURRENCY AND PRICING 18
1.5 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
2.2 MARKET SIZE ESTIMATION 21
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.4 MARKET SHARE ESTIMATION 24
2.5 KEY DATA FROM SECONDARY SOURCES 24
2.6 KEY DATA FROM PRIMARY SOURCES 25
2.6.1 KEY INDUSTRY INSIGHTS 26
2.7 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 32
4.1 GROWTH POTENTIAL OF THE PLASMA FRACTIONATION MARKET 32
4.2 ASIA-PACIFIC PLASMA FRACTIONATION MARKET 33
4.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 34
4.4 NORTH AMERICA DOMINATES THE PLASMA FRACTIONATION MARKET DURING THE FORECAST PERIOD 35
4.5 PLASMA FRACTIONATION MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 35
4.6 PLASMA FRACTIONATION MARKET, BY END USER: GEOGRAPHIC MIX 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 MARKET SEGMENTATION 38
5.2.1 PLASMA FRACTIONATION MARKET, BY PRODUCT 38
5.2.2 PLASMA FRACTIONATION MARKET, BY APPLICATION 38
5.2.3 PLASMA FRACTIONATION MARKET, BY END USER 39
5.3 MARKET DYNAMICS 39
5.3.1 MARKET DRIVERS 40
5.3.1.1 Growing use of immunoglobulin in various therapeutic areas 40
5.3.1.2 Rise in aging population worldwide 41
5.3.1.3 Growing prevalence of emphysema and AATD driving the uptake of alpha-1 antitrypsin 42
5.3.2 MARKET RESTRAINTS 42
5.3.2.1 High cost and limited reimbursement 43
5.3.2.2 Stringent government regulations 43
5.3.2.3 Emergence of recombinant alternatives 43
5.3.3 MARKET OPPORTUNITIES 44
5.3.3.1 Increasing number of hemophilic patients 44
5.3.4 MARKET CHALLENGES 44
5.3.4.1 Pricing pressure faced by prominent players in the market 45
6 INDUSTRY INSIGHTS 46
6.1 INTRODUCTION 46
6.2 INDUSTRY TRENDS 46
6.2.1 RISING NEW INDICATIONS FOR PLASMA PRODUCTS 47
6.2.2 RISING ADOPTION OF SCIG 47
6.2.3 GROWING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 47
6.2.4 GROWING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPMENT OF RECOMBINANT FACTORS 48
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 49
6.3 PORTER’S FIVE FORCES ANALYSIS 52
6.3.1 THREAT FROM NEW ENTRANTS 53
6.3.2 THREAT FROM SUBSTITUTES 53
6.3.3 BARGAINING POWER OF SUPPLIERS 53
6.3.4 BARGAINING POWER OF BUYERS 54
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 54
6.4 STRATEGIC BENCHMARKING 55
6.4.1 INCREASING FRACTIONATION CAPACITY AND GEOGRAPHICAL EXPANSIONS TO DRIVE THE MARKET 55
7 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT 57
7.1 INTRODUCTION 58
7.2 ALBUMIN 60
7.3 IMMUNOGLOBULIN 61
7.3.1 INTRAVENOUS IMMUNOGLOBULIN 62
7.3.2 SUBCUTANEOUS IMMUNOGLOBULIN 63
7.3.3 OTHERS 64
7.4 COAGULATION FACTOR CONCENTRATES 66
7.4.1 FACTOR VIII 68
7.4.2 FACTOR IX 69
7.4.3 FACTOR XIII 70
7.4.4 PROTHROMBIN COMPLEX CONCENTRATE 71
7.4.5 VON WILLEBRAND FACTOR (VWF) 72
7.4.6 FIBRINOGEN CONCENTRATES 73
7.5 PROTEASE INHIBITORS 74
7.6 OTHER PLASMA PRODUCTS 75
8 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION 77
8.1 INTRODUCTION 78
8.2 NEUROLOGY 79
8.3 HEMATOLOGY 81
8.4 IMMUNOLOGY 82
8.5 CRITICAL CARE 84
8.6 OTHER APPLICATIONS 85
9 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER 86
9.1 INTRODUCTION 87
9.2 HOSPITALS AND CLINICS 88
9.3 CLINICAL RESEARCH LABORATORIES 90
9.4 ACADEMIC INSTITUTES 91
10 GLOBAL PLASMA FRACTIONATION MARKET, BY GEOGRAPHY 93
10.1 INTRODUCTION 94
10.2 NORTH AMERICA 96
10.2.1 U.S. 100
10.2.2 CANADA 103
10.3 EUROPE 107
10.3.1 GERMANY 111
10.3.2 ITALY 114
10.3.3 SPAIN 117
10.3.4 FRANCE 120
10.3.5 U.K. 123
10.3.6 REST OF EUROPE (ROE) 126
10.4 ASIA-PACIFIC 129
10.4.1 JAPAN 134
10.4.2 CHINA 136
10.4.3 INDIA 140
10.4.4 REST OF ASIA-PACIFIC (ROAPAC) 142
10.5 REST OF THE WORLD (ROW) 146
10.5.1 LATIN AMERICA 148
10.5.2 MIDDLE EAST AND AFRICA 152
?
11 COMPETITIVE LANDSCAPE 155
11.1 OVERVIEW 155
11.2 MARKET SHARE ANALYSIS 157
11.3 COMPETITIVE SITUATION AND TRENDS 159
11.3.1 EXPANSIONS 159
11.3.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND ALLIANCES 160
11.3.3 NEW PRODUCT LAUNCHES 161
11.3.4 MERGERS AND ACQUISITIONS 162
11.3.5 PRODUCT ACQUISITION 162
12 COMPANY PROFILES 163
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 163
12.2 BAXTER INTERNATIONAL, INC. 164
12.3 OCTAPHARMA AG 167
12.4 BIOTEST 170
12.5 CSL LTD. 173
12.6 GRIFOLS INTERNATIONAL S.A. 176
12.7 KEDRION S.P.A. 179
12.8 LFB 183
12.9 SANQUIN BLOOD SUPPLY FOUNDATION 185
12.10 BIO PRODUCT LABORATORY LTD. (BPL) 187
12.11 CHINA BIOLOGIC PRODUCTS, INC. 188
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
13 APPENDIX 190
13.1 INSIGHTS OF INDUSTRY EXPERTS 190
13.2 AVAILABLE CUSTOMIZATIONS 190
13.3 RELATED REPORTS 191
13.4 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 192